Audible Premium Plus. $0.99/mo for the first 3 months + $20 Audible credits. 12 days only. Get this deal. Cancel anytime.

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Nov 8 2024
Length: 48 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Please try again

Unfollow podcast failed

Please try again

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

Listen for free

View show details

Summary
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:

Dr. David Russler-Germain

Dr. Tycel Phillips

We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?

Stay tuned to find out!

Show more Show less

Show more Show less

What listeners say about Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon